BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics and oral bioavailability of hydrocortisone. 1991

H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Department of Pharmaceutics, University of Florida, Gainesville 32610.

The pharmacokinetics of 20 mg hydrocortisone were studied after IV and oral administration. Endogenous hydrocortisone was suppressed by dexamethasone administration. Hydrocortisone concentrations were measured in plasma and saliva. After IV administration, hydrocortisone was eliminated with a total body clearance of 18 L/hr and a half-life of 1.7 hr. The volume of distribution was 34 L. Oral bioavailability averaged 96%. Absorption was rapid, achieving maximum hydrocortisone levels of 300 ng/mL after 1 hour. Saliva levels were not proportional to plasma levels, but could be shown to reflect free, non-protein bound hydrocortisone concentrations in plasma.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Pharmacokinetics and bioavailability of oral ifosfamide.
May 1986, Arzneimittel-Forschung,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis.
June 1992, Alimentary pharmacology & therapeutics,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Clinical pharmacokinetics and oral bioavailability of ketobemidone.
January 1980, European journal of clinical pharmacology,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Absolute bioavailability and pharmacokinetics of oral teniposide.
April 1992, Seminars in oncology,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Pharmacokinetics and bioavailability of oral and intramuscular artemether.
January 1997, European journal of clinical pharmacology,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Pharmacokinetics and relative bioavailability of oral theophylline capsules.
November 1979, Journal of pharmaceutical sciences,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Bioavailability and pharmacokinetics of oral dopamine in dogs.
July 1988, Journal of pharmaceutical sciences,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Pharmacokinetics and oral bioavailability of pyridostigmine in man.
November 1980, European journal of clinical pharmacology,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.
June 2018, Journal of analytical toxicology,
H Derendorf, and H Möllmann, and J Barth, and C Möllmann, and S Tunn, and M Krieg
Pharmacokinetics and oral bioavailability of pidotimod in humans.
December 1994, Arzneimittel-Forschung,
Copied contents to your clipboard!